Business
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to
About this update from Absci Corporation
[{"type":"text","content":"Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci’s expanding pipeline of AI-designed therapeutics. Dr. Somaratne is a physician-scientist and seasoned biopharmaceutical executive who joins Absci from Vertex Pharmaceuticals, where he served as Senior Vice President of Clinical Development. He previously held various scientific leadership roles at BioMarin Pharmaceutical and Amgen. “Ransi is a proven clinical leader, and we’re excited to have him join Absci at a moment when our AI-designed pipeline is rapidly advancing through clinical development,” said Sean McClain, Founder & CEO of Absci. “His wealth of experience will enhance our clinical development strategy and execution capabilities as we advance multiple programs, including our flagship ABS-201 program toward clinical proof of concept.” A cardiologist and internist by training, Dr. Somaratne’s career is defined by work on multiple pioneering clinical development programs, including the Hemophilia A gene therapy RoctavianⓇ, the development and global approvals of a PCSK9 inhibitor RepathaⓇ, and the development and approval of JournavxⓇ, the first NaV1.8 inhibitor approved for moderate to severe acute pain. He earned his Doctor of Medicine (MD) degree from Albany Medical College in Albany, NY, and also holds a Masters in Business Administration (MBA) from the University of North Carolina at Chapel Hill. He has co-authored over 30 papers in peer-reviewed medical journals, including the New England Journal of Medicine and the Journal of the American Medical Association. “I am excited to join Absci at such a pivotal moment, when the AI Drug Creation Engine has already yielded multiple clinical-stage programs,” said Ransi Somaratne. “I look forward to advancing the development of a truly innovative pipeli...